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ABSTRACT 
By integrating knowledge gained by pharmacogenetic, neuroanatomical and pharmacological studies, a model can be constructed how serotonin (5-
HT) affects the vulnerability to induce tardive dyskinesia. From neuroanatomical studies, it can be concluded that 5-HT inhibits the release of 
dopamine (DA) within the dorsal striatum by affecting 5-HT2C receptors and also within the ventral striatum and prefrontal cortex by affecting 5-
HT2A receptors. However, considering the low affinity of DA for its receptors, it is unlikely that the so released DA is able to displace atypical 
antipsychotics from DA D2 and D3 receptors. 5-HT2C receptors and, to a lesser extent, 5-HT2A receptors, have constitutive activity and therefore, 
atypical antipsychotics can have inverse agonistic effects. It is hypothesized that decreasing the activity of 5-HT2 receptor carrying medium spiny 
neurons (MSNs) within the dorsal striatum represents the mechanism showing how atypical antipsychotics have limited ability to cause tardive 
dyskinesia. 
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INTRODUCTION 
Dyskinesia is a movement disorder characterized by involuntary, 
repetitive and irregular motions that affect the mouth and face 
and/or the limbs and trunk [1, 2]. Dyskinesia can occur 
spontaneously, particularly in elderly patients [3, 4], and in persons 
with schizophrenia [5-7], in Huntington’s disease and in a variety of 
other neurological disorders [8], and can be drug-induced [9]. The 
usage of antipsychotic drugs and levodopa, in particular has been 
associated with dyskinesia. Tardive dyskinesia (TD) is a well-known 
complication of long-term treatment with dopamine (DA) blocking 
agents, predominantly antipsychotic drugs [10]. Levodopa-induced 
dyskinesia (LID) is a common consequence of the long-term 
treatment of Parkinson’s disease with levodopa [11-14]. 
Both LID and TD are believed to be caused by a dysregulation of the 
DAergic neurotransmitter system. A well-accepted model of LID states 
that the mechanism underlying these movements is related to 
pulsatile stimulation of postsynaptic DA receptors [14]. A classical 
model of the pathogenesis of TD explains this movement disorder to 
be a super sensitivity response to chronic DA blockade [15]. However, 
the 5-HTergic system is also believed to be involved [15-18].  
Seven types of serotonin (5-hydroxytryptamine; 5-HT) receptors 
have been found, all but one (5-HT3) being g-protein coupled [19-
21]. Most of these are divided into several subtypes. For their role in 
dyskinesia, 5-HT1A, 5-HT2A and 5-HT2C receptors have been most 
extensively studied [17, 22]. Stimulation of 5-HT1A receptors result 
in increased influx of K+
Pharmacogenetic studies describe an association between 
polymorphisms of the genes coding for the 5-HT2A (HTR2A) and 5-
HT2C (HTR2C) receptor protein and the prevalence of tardive 
dyskinesia. The results appear to be conflicting [25], however. The 
23Ser allele of the Cys23Ser variants of HTR2C (rs6318) was 
associated with an increased risk of TD and Parkinsonism [26-30]. 
The HTR2C is found on the long arm of the X-chromosome, Xq24 
[31]. Males, therefore, are hemizygotes, so always homozygous. Al 
Hadithy et al. demonstrated there was a significant association 
between carriers of the 23Ser allele of HTR2C and Parkinsonian 
bradykinesia in males, but not in females [26]. Wilffert et al. did not 
find a correlation between TD and 23Ser male carriers when they 
were analyzed separately [30]. Orofacial and limb-truncal TD scores, 
however, were statistically significantly higher in male patients 
carrying combinations of the 9Ser variant of the DA D3 (DRD3) gene 
and 23Ser allele of HTR2C [30]. This may correspond to the findings 
of Segman et al., who found no association with 23Ser male carriers, 
but the highest orofacial dyskinesia scores were found in combined 
carriers of 9Gly DRD3 and 23Ser HTR2C (not specified for males and 
females) [29]. Gunes et al., who studied only male subjects with 
several types of EPS (Parkinsonism, dystonia, and/or dyskinesia), 
observed a strong association with 23Ser HTR2C carriers [28]. It 
should be emphasized that the drug treatments probably differed 
between studies. Gunes et al. excluded all patients who were using 
atypical drugs,[28] while the other authors included patients who 
were on atypical antipsychotics [26,27,30]. Unfortunately, Segman et 
al. did not specify the antipsychotics used by their patient 
population, but they studied Jewish patients recruited from several 
centers in Israel [29, 32].  
ions and hyperpolarization of the 
membrane, and so to the inhibition of neurotransmission while 5-
HT2A and 5-HT2C receptors have opposite activity [19-24]. 
Atypical antipsychotics are assumed to cause less Parkinsonism and 
TD by blocking 5-HT2A and/or 5-HT2C (5-HT2A/2C) receptors [33-
36], therefore, the differences between the results of these studies 
may at least be partly explained by the concurrent use of 5-HT2A/2C 
blocking agents by at least some of the patients, which apparently 
decrease the differences between carriers and non-carriers. In 
future studies, users of 5-HT2A/2C blocking agents should be 
excluded from analysis. 
In this article, we will try to explain the association between being a 
carrier of this 23Ser HTR2C, and the likelihood of developing TD by 
describing the distribution and physiological role of this receptor. 
Anatomical considerations 
5-HT is, together with DA, norepinephrine (NE) and histamine (H), 
one of the lesser abundant neurotransmitters of the central nervous 
system (CNS), which are used by about 2% of the CNS nerve cells 
[19]. Cell bodies of 5-HTergic neurons are primarily localized in a 
group of five nuclei near the midline (‘raphe’ from Greek ῥαφή) of 
the brainstem (fig. 1). Apart from these proper raphe nuclei, three 
other nuclei have been described [37]. These nuclei are usually 
divided into upper and lower raphe nuclei. From there, at least six 
bundles of fibers can be distinguished, which run up and down to 
most parts of the CNS, including a bundle running to preganglionic 
sympathetic neurons of the thoracic intermediolateral column 
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within the spinal cord and one up through the medial forebrain 
bundle to the striatum and cerebral cortex [19, 37]. Within the 
brainstem, 5-HTergic nuclei are connected to the DAergic substantia 
nigra, pars compacta (SNc) and ventral tegmental nucleus (VTA), to 
adrenergic (NE using) locus coeruleus and nucleus tractus solitarius 
and to other 5-HTergic raphe nuclei [19, 37]. 
 
 
Fig. 1: Serotonergic system [19] 
 
B1: nucleus raphes pallidus, B2: nucleus raphes obscurus, B3 
nucleus raphes magnus, B5 nucleus raphes pontis, B7 nucleus 
raphes dorsalis, B6+B8: nucleus centralis superior, B4 and B9 
innominate cell groups. 
In order to understand how 5-HT2 receptors modify Parkinsonism 
and TD, the exact localization of 5-HT2A and 5-HT2C receptors 
within several areas of the brain should be considered. This 
localization is not entirely clear within the cerebral cortex [36, 38]. 
5-HT2A receptors are abundantly present in the telencephalon 
(olfactory system, cerebral cortex, basal forebrain, neostriatum, and 
hippocampus), and occur in the diencephalon and brainstem [36]. 5-
HT2C receptors are more abundant and more widely expressed than 
5-HT2A receptors, but the two types of receptors often co-exist [36].  
 
 
Fig. 2: Schematic representation of extrapyramidal system with 
direct and indirect pathways [19] 
D1 = dopamine D1 receptor carrying MSNs, D2 = dopamine D2 
receptor carrying MSNs, DYN = dynorphin, ENK = enkephalin, GPe = 
globus pallidus external part, GPi = globus pallidus internal part, SNc 
= substantia nigra pars compacta, SNr = substantia nigra pars 
reticulata, SP = substance P, STh = subthalamic nucleus; in red = 
excitatory pathways, in blue = inhibitory pathways. 
Within the cerebral cortex, 5-HT2A receptors are localized on 
pyramidal cells, on Gamma Amino Butyric Acid (GABA)ergic 
interneurons, and pre-synaptically on axons of (probably) 
monoaminergic cells (fig. 3). However, although results are 
conflicting, 5-HT2C receptors are probably not present on fast-
spiking (i.e. GABAergic) interneurons of the cerebral cortex [36, 
38, 39]. Within the basal ganglia, 5-HT2A and 5-HT2C receptors 
are co-localized within medium-sized spiny projection neurons 
(MSNs) of both direct and indirect pathways of the extrapyramidal 
circuit (fig. 2 and 4) [36]. Moreover, both 5-HT2A and 5-HT2C 
receptors are present on cholinergic, glutamatergic, and DAergic 
axon terminals [38]. The simultaneous role in GABAergic 
interneurons is less clear. 5-HT acts on 5-HT2C receptors when 
stimulating striatal fast-spiking interneurons, which are the most 
numerous class of GABAergic interneurons there [40]. To the best 
of our knowledge, a physiological role has never been established 
for 5-HT2A receptors. Within the upper brainstem, 5-HT2C 
receptors are restricted to GABAergic neurons, at least within pars 
reticulata and pars compacta (SNc) of the substantia nigra (fig. 5). 
Only few 5-HT2C receptor positive cells were observed within the 
VTA [41]. However, 5-HT2A receptors were more often present 
within neurons in the VTA than those in the SNc [42]. Within the 
VTA, 5-HT2A receptors are unevenly distributed and more 
prevalent in rostral and mid parts [43]. They are co-localized with 
DAergic neurons throughout the VTA, but they also co-localized 
with non-DAergic cells [43]. These differences in the distributions 
of 5-HT2A and 5-HT2C receptors may explain the various effects of 
5-HT agonists and antagonists in different parts of the midbrain. 
Within the VTA, they predominantly act on 5-HT2A receptors with 
a direct effect on DAergic neurons, while within the SNc, they 
predominantly act on 5-HT2C receptors of GABAergic 
interneurons.  
It can be concluded that 5-HT inhibits the activity of DA terminals 
within the dorsal striatum, mainly by affecting 5-HT2C receptors. It 
inhibits DA activity within the ventral striatum and frontal cortex 
mainly by affecting 5-HT2A receptors. 
 
 
Fig. 3: Distribution of 5-HT2A and 5-HT2C receptors within the 
prefrontal cortex [19] 
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Fig. 4: Distribution of 5-HT2A and 5-HT2C receptors within the striatum [original] 
 
Fig. 5: Distribution of 5-HT2A and 5-HT2C receptors within the midbrain [original] 
 
 
Table 1: Receptor-binding affinities (expressed as Ki values) of several atypical antipsychotic agents in comparison to haloperidol 
 Clozapine Olanzapine Quetiapine Ziprasidone Sertindole Aripiprazol Asenapine Risperidon Paliperidon Pipamperon Ritanserin Haloperidol 
D1 85 31 455 9.5 12 265 1.4 75 670 - - 25 
D2 125 11 160 4.8 0.45 0.34 1.4 3 4.0 124 70 1 
D3 473 49 340 7.2 12 0.8 0.42 10 7.5 - - 2 
D4 9 27 1600 32 11 44 1.1 7 30 - - 5 
D5 235 90 1738 152 - 1675 - 16 29 - - 147 
5-HT 12 2A 4 220 0.4 0.2 3.4 0.07 0.6 0.25 7 1.0 78 
5-HT 8 2C 11 615 1.3 0.51 15 0.034 26 71 54 9.3 3085 
α 7 1 19 7 10 1.4 57 1.2 2 4.0 62 97 46 
H 6 1 7 11 47 440 61 1.0 155 10 >> 35 3630 
M 1,9 1 1.9 120 >> 260 >> >> >> 3570 2.500 - 1475 
Aripiprazole [Abilify package insert]; asenapine [50]; olanzapine [Zyprexa package insert]; paliperidone [51]; pipamperone [52, 53]; ritanserin [54]; sertindole [55]; ziprasidone [Gideon package insert]; 
D5: [22, 56, 57]. 
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How antagonizing 5-ht2 receptor does limits Parkinsonism and 
dyskinesia 
An initial model to explain how atypical antipsychotics cause less 
extrapyramidal side effects than classical drugs was related to the 
observation that antagonists of 5-HT2 receptors block the inhibition 
of release of DA by 5-HT from striatal slices in vitro [44]. It was 
suggested that 5-HT had this effect by stimulating 5-HT2 receptors 
on DAergic terminals. Later, it was shown that numerous atypical 
antipsychotics stimulate the release of DA more potently in the 
medial prefrontal cortex and mesocorticolimbic innervated areas 
than in the striatum [45]. This is not only attributed to direct effects 
on DAergic terminals, but also influencing their origins within the 
midbrain. However, 5-HT2C receptors mediate an inhibitory effect 
on the release of DA within the dorsal and ventral striatum [45, 46]. 
As has been stated above, both 5-HT2A and 5-HT2C receptors have 
an excitatory effect [19-21], so blocking these receptors with 
atypical antipsychotics would result in inhibition of the DAergic cell 
bodies/terminals and therefore, result in inhibition of DA release. 
This apparent contradiction can be explained by their localization on 
GABAergic inhibitory interneurons [47].  
Stimulation of these interneurons results in inhibition of the activity 
of DAergic cells and nerve terminals; blocking these 5-HT2 receptors 
would result in increased release of DA [19]. Based on this theory, it 
was believed that atypical antipsychotics induce the release of DA to 
such an extent that some of the DA D2 receptor blockades by the 
antipsychotic drug was reversed [48]. However, an important 
pharmacological reason causes doubt concerning this mechanism. 
As can be seen in table 1, apart from clozapine, quetiapine, and 
pipamperone, most atypical antipsychotics are potent DA D2 
receptor antagonists. DA itself has an affinity in the micromolar range 
[49]. It is difficult to understand how the even massive release of DA 
would be able to displace most atypical antipsychotics to a sufficient 
degree from their DA D2 receptor. In fact, this mechanism would 
overload the putamen with DA, leading to an increase in oxidative 
stress. This may result in an increase of TD by causing damage to 
medium sized GABAergic projection neurons (MSNs) [10].  
Apart from promoting DA release from striatal DAergic fibers, 5-HT2 
receptors may modulate the activity of striatal GABAergic projection 
neurons (MSNs) directly (fig. 4). These receptors are present on 
MSNs of both direct and indirect pathways. A special characteristic 
of these receptors can explain why 5-HT2 antagonists diminish 
Parkinsonism and decrease the likelihood of developing dyskinesia: 
these receptors spontaneously signal for cellular effector 
mechanisms in the absence of ligands [38, 58], and 5-HT2C 
receptors may have higher constitutive activity than 5-HT2A. In this 
situation, a ligand binding to the receptor may also act as an inverse 
agonist; i.e., changing the activity of the receptor in the opposite 
direction instead of increasing or blocking it. This occurred when 
this receptor was bound by atypical antipsychotics [22, 38]. This 
may also explain the findings from genetic studies. In these cases, 
the genetic variant (of 5-HT2A or 5-HT2C receptors) with increased 
constitutive activity would have greater benefit and the variant with 
decreased or absent constitutive activity would have less benefit due 
to the complete blockade of these receptors by atypical 
antipsychotic drugs. In the absence of receptor blockers (usage of 
classical antipsychotics), carriers of a variant with no constitutive 
activity would have a significant advantage. As is shown in table 1, 
most atypical antipsychotics are both 5-HT2A and 5-HT2C 
antagonists. Inverse agonism is somewhat more likely with 5-HT2C 
than 5-HT2A receptors [38]. Moreover, inverse agonism at 5-HT2C 
receptors may also explain the prevention of TD by having a direct 
influence on MSNs and/or an indirect effect on corticostriatal 
projections. Inverse agonistic effects (less activation) on MSNs of the 
indirect pathway could explain the occurrence of less Parkinsonism 
as well as protection against excitatory toxicity [10]. 
CONCLUSION 
Considering the distribution of these receptors and the low affinity 
of DA to receptors of the DA D2 receptor family, it seems unlikely 
that atypical antipsychotics have a low potential to cause 
Parkinsonism by increasing DA release within the striatum. Only 
clozapine, quetiapine and pipamperone have such low affinity to the 
D2 receptors that DA could successfully compete with them for 
binding to this receptor. 
An exception may be binding to the Ser9Gly DRD3 variant (rs6280) 
of the DA D3 receptor [59]. The homogenous Gly variant has been 
associated with four-fold greater DA binding affinity in vitro [60] and the 
DA D3 receptor is characterized by an extraordinary large binding 
affinity for DA [61]. It should be emphasized, however, that DA D3 
receptors are largely confined to the ventral striatum [61], while the 
site of action of TD inducing mechanisms should be the putamen [10]. 
So, even in this case, promoting DA release is an unlikely mechanism 
to overcome antipsychotic drug-induced Parkinsonism. Furthermore, 
even when DA would have sufficient affinity to compete with 
antipsychotics for binding to the homogenous Ser9Gly variant of the 
DA D3 receptor, it is difficult to understand how this activation could 
overcome the remaining blockade of DA D2 and D4 receptors within 
the dorsal striatum.  
Whether the affinity of atypical antipsychotics to DA D1 and D5 
receptors is sufficiently low to have these drugs displaced by extra 
released DA (table 1), is not certain, but definitely more likely: this 
could be related to the cognitive effects of atypical antipsychotics 
[22]. Moreover, the release of DA within the prefrontal cortex has a 
higher magnitude than that within the dorsal striatum possibly by 
the involvement of 5-HT2A receptors [45]. The release of DA within 
the prefrontal cortex and striatum may be relevant in case of 
antidepressant drugs because these agents have a very low affinity 
to DA receptors [62]. 
So, when the promoting of DA release is not the best explanation for 
the reduced capability of 5-HT2 receptor antagonists to induce 
Parkinsonism and TD in comparison to classical antipsychotics, an 
alternative explanation comes into view. We want to hypothesize 
that this is caused by blocking the constitutive excitatory activity of 
5-HT2 receptors on striatal MSNs (fig. 4). This would decrease the 
activation of both direct and indirect extrapyramidal pathways, 
thereby reducing the risk of Parkinsonism, especially when the 
direct pathway is still activated by stimulation of DA D1 carrying 
MSNs. At the same time it would lower the vulnerability of these 
medium spiny neurons (MSNs) to neurotoxicity resulting from 
oxidative stress, therewith preventing TD [10].  
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